Recently, Zelixir Biotech and Viva Biotech signed a strategic cooperation agreement and formed a partnership. Based on the complementary nature of their respective businesses and technologies, the two parties have launched an in-depth collaboration on research related to high-throughput, AI-assisted drug design and the molecular discovery of new drugs.
This cooperation recognizes Zelixir Biotech's algorithm and platform delivery capabilities, while displaying the importance of Zelixir Biotech in Viva Biotech's strategy. According to the agreement, both parties will give full play to their respective expertise. Because of the preclinical drug developments of Viva, combined with Zelixir's expertise in AI-based protein structure calculations, molecular screening design, molecular dynamics simulations, and free energy perturbation, new ways of drug development can be explored. These new findings will improve the accuracy and efficiency of drug molecule discovery and optimization.